logo
logo

Kortuc Inc. Closed Financing From Axa Japan To Accelerate Pivotal Phase Ii Study Of Novel Radiosensitizer For Cancer Radiotherapy

Jul 29, 2021•almost 4 years ago
London

Description

Today KORTUC Inc., a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), announces the closing of an equity investment from AXA Japan.

Company Information

Company

Kortuc

Location

London, Ontario, Canada

About

KORTUC will use the financing to fund Research and Development activities, accelerate its Pivotal Phase II Study in the UK and pursue additional Pivotal Studies in the US. Boris Moutier, Corporate Officer of AXA Japan, Japan and Asia Chief Investment Officer, also highlights that “With this brand new radiosensitizer, KORTUC has great potential to become a ground-breaking player in cancer treatment field, and we are glad to engage in this greatly promising journey.